3D Systems Corp: Form 10-Q for the period ended Mar 31, 2024
Filed with the SEC on Aug 20, 2024 and accepted by EDGAR at Aug 20, 2024, 16:34 ET.
Management's discussion and analysis
As filed, 62,913 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following discussion and analysis should be read together with our unaudited condensed consolidated financial statements and notes thereto included in Item 1 of this Quarterly Report on Form 10-Q (the “Financial Statements”). Certain statements contained in this discussion may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks, uncertainties and other factors that may affect our future performance that are discussed in greater detail under the heading “Forward Looking Statements” below and in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2023 (“2023 Form 10-K”).
Business Overview
3D Systems Corporation (“3D Systems” or the “Company” or “we,” "our" or “us”) markets our products and services through subsidiaries in North America and South America (collectively referred to as “Americas”), Europe and the Middle East (collectively referred to as “EMEA”) and Asia Pacific and Oceania (collectively referred to as “APAC”). We provide comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, and services, including maintenance, advanced manufacturing and applications engineering. Our solutions support advanced applications in two key industry verticals: Healthcare Solutions and Industrial Solutions. We have over 35 years of experience and expertise, which have proven vital to our development of an ecosystem and end-to-end digital workflow solutions that enable customers to optimize product designs, transform workflows, bring innovative products to market and drive new business models.
The Company has two reportable segments: Healthcare Solutions and Industrial Solutions. Our reportable segments are based upon the industry verticals that they serve. For Healthcare Solutions, those industry verticals include dental, medical devices, personalized health services and regenerative medicine. For Industrial Solutions, those industry verticals include aerospace, defense, transportation and general manufacturing. We architect solutions specific to customers’ needs through a combination of materials, hardware platforms, software, professional services and advanced manufacturing – creating a path to integrating additive manufacturing into traditional production environments. As a result, manufacturers achieve design freedom, increase agility, scale production and improve their overall total cost of operation. Our technologies and process knowledge enable over a million production parts to be made through additive manufacturing each day.
Recent Developments and Updates Regarding Strategic Initiatives
Ongoing Fiscal Year 2023 Restructuring Plan
Restructuring Plan Objectives and Status of Execution
In 2023, the Company commenced a multi-faceted restructuring plan (the “2023 Restructuring Plan”) to improve operating efficiencies throughout the organization and drive long-term value creation. The key initiatives of the plan, some of which are ongoing, were announced throughout 2023 and have included:
- improving manufacturing efficiencies related to the Company’s European metal printer operations by (1) in-sourcing certain metal printer platforms into the Company’s Riom, France manufacturing facility and (2) co-locating the engineering and manufacturing of in-sourced metal printer products in order to improve cycle time from development to production;
- reducing headcount throughout all functions and areas of the organization;
- rationalizing the Company's geographic footprint through the exit of leased facilities; and
- reducing certain third-party costs.
As of March 31, 2024, the Company has substantially completed its in-sourcing activities. Actions taken to reduce headcount commenced during the year ended December 31, 2023 and continued throughout the quarter ended March 31, 2024. Beginning during our fourth quarter ended December 31, 2023, and continuing throughout the quarter ended March 31, 2024, the Company (1) has been identifying and evaluating its opportunities to exit leased facilities, (2) has been both developing and starting to execute against its relocation plans, and (3) has begun to market facilities that have been successfully exited for sublease. The decision-making, planning and execution related to our planned facility exits will continue throughout 2024.
2023 Restructuring Plan Costs, Cash Settlements and Recognized Liabilities
Since inception of the 2023 Restructuring Plan, we have incurred $8.3 million related to headcount reductions. These charges relate to employee severance and termination benefit costs that are generally recognized when probable and estimable because they are typically being determined consistent with the Company’s past practices or statutory law. We currently expect aggregate costs related to our headcount reduction activities to be in the range of $9.0 million to $10.0 million when this initiative is completed.
We expect to incur additional cash expenditures related to our planned facility exits and relocation activities, which will be recognized as incurred. We also may incur non-cash impairment charges as a result of exiting leased facilities, if the carrying values of the related right-of-use asset balances and other related asset balances (e.g., leasehold improvements) will not be fully recoverable through our efforts to sublease an exited facility. Since inception of our 2023 Restructuring Plan, our consolidated financial statements have not reflected material transactions or charges resulting from decisions to exit facilities because either (1) the Company has not ceased use of a facility that it plans to exit or (2) an individual facility (inclusive of any related assets, as applicable) does not yet qualify to be measured for impairment separate from the asset group to which it has historically belonged, which would generally occur when we have entered into a sublease.
We currently expect the execution of our restructuring plan, including the cash settlement of associated liabilities, to be substantially complete by December 31, 2024. Further, we expect our combined restructuring initiatives, inclusive of those that have commenced, to deliver aggregate annualized savings of between $45.0 million and $55.0 million upon completion of the restructuring plan.
Other Strategic Business Decisions and Cost Saving Initiatives
dp polar
During the year ended December 31, 2023, the Company ceased the development of the in-process research and development ("IPR&D") acquired in connection with our October 2022 acquisition of dp polar GmbH ("dp polar") and fully impaired the carrying value of the long-lived assets attributable to this asset group. To date, the primary impact of this decision has been the recognition of lower amortization expense attributable to intangible assets for the three months ended March 31, 2024.
Oqton
Throughout the three months ended March 31, 2024, the Company continued to evaluate strategic alternatives related to Oqton, Inc. ("Oqton") MOS, for which the Company previously disclosed, during the year ended December 31, 2023, that it is more likely than not the business would be sold or otherwise disposed of. In connection with the expectation to sell or otherwise dispose of Oqton MOS, management previously assessed whether the carrying value of this asset group’s long-lived assets was recoverable, resulting in a full impairment of the asset group's intangible assets during the year ended December 31, 2023. No incremental impairment charges were recognized with respect to the carrying values of the asset group's other assets during the three months ended March 31, 2024. As a result of the impairment of Oqton MOS’s intangible assets during the year ended December 31, 2023, the Company has recognized lower amortization expense attributable to intangible assets for the three months ended March 31, 2024.
During May 2024, the Company completed the sale of the portion of the Oqton MOS business that was focused on the dental market ("Oqton Dental") in exchange for a de minimis amount of cash, resulting in the transfer of a limited portion of Oqton MOS's personnel and a de minimis amount of fixed assets. The sale of Oqton Dental does not qualify as a discontinued operation as it does not represent a strategic shift that will have a major effect on our overall business operations; however, the transfer of personnel is expected to provide cost savings from the date of the disposal of Oqton Dental. The Company continues to evaluate strategic alternatives related to the remaining portion of Oqton MOS that the Company continues to hold.
Investing in Regenerative Medicine
Within our Healthcare Solutions segment, a portion of our business focuses on opportunities for additive manufacturing to be applied to regenerative medicine. To date, our efforts in the area of regenerative medicine have consisted primarily of pre-commercial bio-technology research and development (“R&D”) in the areas described below.
Our first area of focus is the use of additive manufacturing for human organ transplantation, with a long-term goal of helping patients with end-stage disease receive transplants that will enable them to enjoy long and active lives. This program combines our 3D printing expertise and capabilities in human tissue engineering with the regenerative medicine and biotechnology expertise of a key strategic partner. Through the start of 2024, our program focused on developing the capability to print organ scaffolds for human lungs, kidneys and livers. However, beginning in the first quarter of 2024, due to changes to our arrangement with and funding from our key strategic partner, the Company’s continuing organ program shifted its focus to developing the capability to print human lung scaffolds, for which the related R&D efforts will continue to be primarily funded by our key strategic partner. Refer to Note 11, Note 16, and Note 19 to the condensed consolidated financial statements included in Item 1 of this Form 10-Q for additional information regarding the impact of the changes to this program during the first quarter of 2024.
Our second area of focus involves utilizing our bio-printing technology to manufacture non-organ human tissue scaffolds for use in transplantation and surgical reconstruction applications. We believe that continued progress in this area could result in significantly improved health outcomes for patients, as well as open up attractive new growth markets and therapeutic applications for 3D printed, vascularized soft-tissue scaffolds.
Our third area of focus seeks to utilize our bio-printing capabilities to design and manufacture 3D-printed vascularized “organs-on-chips” for use in drug development by pharmaceutical industry customers through our wholly-owned biotech company, Systemic Bio. We believe that “organs-on-chips” can accelerate the drug development process and reduce the cost of pre-clinical drug testing, as well as reduce the pharmaceutical industry’s reliance on animal testing. Systemic Bio combines 3D Systems’ legacy expertise in high-resolution 3D printing with advanced capabilities in bioprinting and biomaterials to design and market 3D-printed, vascularized “organs-on-chips”. During the year ended December 31, 2023, Systemic Bio entered into its first commercial contracts with pharmaceutical industry customers.
Acquisition of Wematter (See Note 2 to the Condensed Consolidated Financial Statements for further details.)
On July 1, 2023, the Company completed the acquisition of Wematter AB (“Wematter”), a Swedish 3D printer manufacturer, for which post-acquisition results are included in our Industrial Solutions segment. The acquisition broadens 3D Systems’ Selective Laser Sintering (SLS) portfolio. Consideration for this acquisition consisted of approximately $10.2 million in cash, subject to customary post-closing adjustments. The Company also may be required to pay an additional €2.0 million in cash, contingent upon the achievement of certain post-closing performance conditions and the continued employment of certain key employees of Wematter for two years after the closing date of the acquisition. As of March 31, 2024, management does not believe that achievement of the post-closing performance conditions is probable.
Background
We earn revenue from the sale of products and services through our Healthcare Solutions and Industrial Solutions segments. The product categories include 3D printers and corresponding materials, digitizers, software licenses, 3D scanners and haptic devices. The majority of materials used in our 3D printers are proprietary. The services categories include maintenance contracts and services on 3D printers, software maintenance, software as a service subscriptions and healthcare solutions services.
Given the relatively high price of certain 3D printers and a corresponding lengthy selling cycle, as well as relatively low unit volume of the higher-priced printers in any particular period, a shift in the timing and concentration of orders and shipments from one period to another can materially affect reported revenue in any given period.
In addition to changes in sales volumes, there are two other primary drivers of changes in revenue from one period to another: (1) the combined effect of changes in product mix and average selling prices and (2) the impact of fluctuations in foreign currencies. As used in this Management’s Discussion and Analysis of Financial Condition and Results of Operations ("MD&A"), the price and mix effects relate to changes in revenue that are not able to be specifically related to changes in unit volume or foreign exchange.
How We Assess the Performance of Our Business
We manage operations through the two business segments described above. In addition to our consolidated GAAP financial measures, we review Adjusted EBITDA.
We believe Adjusted EBITDA is a helpful supplemental measure to assist us and investors in evaluating our operating results, as Adjusted EBITDA excludes certain items for which the fluctuation from period to period does not necessarily correspond to changes in the operations of our business. Adjusted EBITDA represents net income (loss), plus income tax (provision) benefit, interest and other income (expense), net, stock-based compensation expense, amortization of intangible assets, depreciation expense, and certain other non-GAAP adjustments. We believe that the adjustments applied in presenting Adjusted EBITDA are appropriate to provide additional information to investors about our operating and financial performance without the effects of (1) certain material non-cash items and (2) certain items that we do not believe to be core to our operations.
Management and our Board of Directors regularly use Adjusted EBITDA in evaluating our operating and financial performance and in establishing discretionary annual compensation. This measure is provided in addition to, and should not be considered to be a substitute for, or superior to, comparable measures determined in accordance with GAAP. In addition, we believe that Adjusted EBITDA is frequently used by investors and other interested parties in the evaluation of other issuers, many of which also present Adjusted EBITDA when reporting their results in an effort to augment investors' understanding of their operating and financial results; however, similarly titled measures provided by other issuers may not be calculated in the same manner and/or using the same adjustments.
Adjusted EBITDA should not be considered as an alternative to net income (loss) or any other performance measure derived in accordance with GAAP. Adjusted EBITDA has limitations as an analytical tool, and you should not consider such measure either in isolation or as a substitute for analyzing our results as reported under GAAP.
For further information regarding Adjusted EBITDA, see “Reconciliation of non-GAAP Measures” below.
Consolidated Financial Results for the Three Months Ended March 31, 2024 and 2023
(in thousands)
| Revenue: | Three Months Ended March 31, 2024 | March 31, 2023 | |
|---|---|---|---|
| Products | $64,051 | $84,388 | |
| Services | 38,854 | 36,848 | |
| Total revenue | 102,905 | 121,236 | |
| Cost of sales: | |||
| Products | 39,587 | 49,880 | |
| Services | 22,396 | 24,258 | |
| Total cost of sales | 61,983 | 74,138 | |
| Gross profit | 40,922 | 47,098 | |
| Operating expenses: | |||
| Selling, general and administrative | 57,304 | 58,285 | |
| Research and development | 23,480 | 22,209 | |
| Total operating expenses | 80,784 | 80,494 | |
| Loss from operations | (39,862) | (33,396) | |
| Interest and other income (expense), net: | |||
| Foreign exchange gain (loss), net | 1,909 | (372) | |
| Interest income | 2,798 | 4,546 | |
| Interest expense | (714) | (741) | |
| Other (expense) income, net | 21,386 | 442 | |
| Total non-operating income | 25,379 | 25379000 | 3,875 |
| Loss before income taxes | (14,483) | (29,521) | |
| Provision for income taxes | (1,371) | (8) | |
| Loss on equity method investment, net of income taxes | (247) | — | |
| Net loss before redeemable non-controlling interest | (16,101) | (29,529) | |
| Less: net loss attributable to redeemable non-controlling interest | (100) | (108) | |
| Net loss attributable to 3D Systems Corporation | $(16,001) | $(29,421) | |
| Other Financial Data: | |||
| Adjusted EBITDA | $(20,060) | $(10,094) |
31
Consolidated Financial Results for the Three Months Ended March 31, 2024 Compared to the Three Months Ended March 31, 2023
Consolidated revenue
The following table sets forth changes in our products and services revenue for the three months ended March 31, 2024 and 2023.
(Dollars in thousands)
| Products | Services | Total | ||||
|---|---|---|---|---|---|---|
| Revenue — three months ended March 31, 2023 | $84,388 | 69.6% | $36,848 | 30.4% | $121,236 | 100.0% |
| Change in revenue: | ||||||
| Volume | (20,003) | (23.7)% | 1,987 | 5.4% | (18,016) | (14.9)% |
| Price/mix | (299) | (0.4)% | 1 | —% | (298) | (0.2)% |
| Foreign currency translation | (35) | —% | 18 | —% | (17) | —% |
| Net change | (20,337) | (24.1)% | 2,006 | 5.4% | (18,331) | (15.1)% |
| Revenue — three months ended March 31, 2024 | $64,051 | 62.2% | $38,854 | 37.8% | $102,905 | 100.0% |
Products revenue
For the three months ended March 31, 2024, products revenue decreased by $20.3 million, or 24.1%, as compared to the three months ended March 31, 2023, which is primarily attributable to lower sales volume. The $20.0 million, or 23.7%, decrease in products revenue due to lower sales volume includes a $25.2 million decrease in revenue that is primarily attributable to lower printers sales, partially offset by a $5.2 million increase in revenue attributable to a higher volume of materials sales. Printer sales volume decreased for the three months ended March 31, 2024 compared to the three months ended March 31, 2023 due to (1) a significant decline in printer sales to our key customer in the dental industry, to which we also expect limited printer sales for the remainder of 2024; (2) certain significant printer sales arrangements occurring during the three months ended March 31, 2023, whereas the Company did not benefit from similar arrangements during the three months ended March 31, 2024; and (3) the general impact of macroeconomic conditions on purchases of our printers due to the capital expenditure nature of such customer purchases. Due to the high price of certain of our 3D printers, our total products revenue has been materially impacted by these period-over-period changes in the concentration of printer orders and shipments.
In addition, products revenue decreased due to the loss of revenue attributable to our regenerative medicine kidney and liver R&D program, as well as a decrease in revenue attributable to our regenerative medicine lung R&D program for which there was lower activity during the quarter ended March 31, 2024. Refer to the discussion of "Investing in Regenerative Medicine" within the "Recent Developments and Updates Regarding Strategic Initiatives" section of this MD&A for additional details regarding the change to our organs R&D program that resulted in the loss of revenue attributable to kidney and liver research.
The decrease in products revenue attributable to the lower volume of printer sales and the decrease in activity performed under our organs R&D program was partially offset by the $5.2 million increase in revenue attributable to a higher volume of materials sales. This increase in volume was primarily driven by increased materials sales to our key customer in the dental industry, which returned to normalized levels during the three months ended March 31, 2024. During the three months ended March 31, 2023, we experienced significantly lower materials sales to this key customer due to the customer's higher inventory on hand during the period. Higher materials sales to our key customer in the dental industry were partially offset by lower materials sales elsewhere in our business, largely driven by higher on-hand inventory at certain customers.
Products revenue for the three months ended March 31, 2024 decreased $0.3 million due to changes in price/mix, which reflects an unfavorable impact of the increased sales of materials to our key customer in the dental industry at favorable pricing as compared to the prior year period, partially offset by the absence of certain larger printer sales arrangements and materials sales arrangements recognized during the three months ended March 31, 2023, for which pricing was discounted.
Services revenue
For the three months ended March 31, 2024, services revenue increased by $2.0 million, or 5.4%, as compared to the three months ended March 31, 2023. This increase was driven by increases in parts manufacturing revenue, an increase in parts and maintenance revenue related to the installed printer base at our key dental industry customer, and revenue generated from a significant services contract that had not been executed as of March 31, 2023.
Total revenue
For the three months ended March 31, 2024, revenue decreased by $18.3 million, or 15.1%, as compared to the three months ended March 31, 2023. This decrease was primarily driven by the $20.3 million decrease in our products revenue, which was only partially offset by a $2.0 million increase in our services revenue. Refer to the discussions of products revenue and services revenue above for additional details.
Consolidated gross profit
(Dollars in thousands)
| Three Months Ended March 31, 2024 Gross Profit | Gross Profit Margin | March 31, 2023 Gross Profit | Gross Profit Margin | Change in Gross Profit $% | Change in Gross Profit Margin Percentage Points% | |||
|---|---|---|---|---|---|---|---|---|
| Products | $24,464 | 38.2% | 34,508 | 40.9% | $(10,044) | (29.1)% | (2.7) | (6.6)% |
| Services | 16,458 | 42.4% | 12,590 | 34.2% | 3,868 | 30.7% | 8.2 | 24.0% |
| Total | $40,922 | 39.8% | $47,098 | 38.8% | $(6,176) | (13.1)% | 1.0 | 2.6% |
Consolidated gross profit and gross profit margin
Our consolidated gross profit for the three months ended March 31, 2024 decreased $6.2 million, or 13.1%, to $40.9 million, as compared to $47.1 million for the three months ended March 31, 2023. Our consolidated gross profit margin increased to 39.8% for the three months ended March 31, 2024, as compared to 38.8% for the three months ended March 31, 2023.
Our consolidated gross profit was negatively impacted by both (1) the significant decrease in revenue from products sales, which represents a significantly greater portion of our total revenue and contributes a significantly greater portion of our total gross profit than services revenue, and (2) the lower gross profit margin realized on our products revenue. However, our consolidated gross profit margin increased 100 basis points due to the significant increase in our services gross profit margin, as well as the increase in services revenue as a percentage of total revenue for the three months ended March 31, 2024, as compared to the three months ended March 31, 2023. Refer to the discussions below for additional details regarding factors that have impacted products and services gross profit and gross profit margin.
Products gross profit and gross profit margin
For the three months ended March 31, 2024, gross profit from products sales decreased by $10.0 million, or 29.1%, as compared to the three months ended March 31, 2023. This decrease in gross profit from products sales is primarily due to the 24.1% decrease in products sales revenue. Further contributing to the decrease in products gross profit, as well as to the 270 basis point decrease in products gross profit margin, was a $2.8 million increase in expense attributable to the increase in our inventory reserve, as well as certain direct inventory write offs.
Services gross profit and gross profit margin
For the three months ended March 31, 2024, gross profit from services sales increased $3.9 million, or 30.7%, as compared to the three months ended March 31, 2023. The increase in services gross profit for the three months ended March 31, 2024, as well as the 820 basis point increase in services gross profit margin, is due to the $2.0 million increase in services revenue for the three months ended March 31, 2024, while services costs of sales decreased by $1.9 million for the period. Reductions in headcount related to our 2023 Restructuring Plan was the primary driver of the lower services costs of sales.
Consolidated selling, general and administrative expense
Selling, general and administrative ("SG&A") expense for the three months ended March 31, 2024 decreased $1.0 million, or 1.7%, to $57.3 million as compared to $58.3 million for the three months ended March 31, 2023. The primary drivers of the $1.0 million decrease in SG&A expense reported for the three months ended March 31, 2024, as compared to the three months ended March 31, 2023, are as follows:
| Primary drivers (in thousands) | Increase / (Decrease) |
|---|---|
| Volumetric earnout | $(3,980) |
| Compensation and benefits | (1,239) |
| Amortization expense | (1,070) |
| Third-party service provider and consulting costs | 5,672 |
| Accrued contingency expense | 1,500 |
| Other | (1,864) |
| Total change | $(981) |
Volumetric earnout expense decreased by $4.0 million for the three months ended March 31, 2024 as the Company is no longer accruing compensation expense related to a $65 million earnout payment that was potentially payable to the sellers of Volumetric pursuant to the terms of the Volumetric acquisition agreement; whereas, the Company was accruing compensation expense related to this potential earnout payment during the three months ended March 31, 2023. During the quarter ended September 30, 2023, the Company concluded that the non-financial, science-based milestone to which the potential earnout payment of $65 million related was no longer probable of being achieved due to a reduction in the budgeted funding for the related R&D efforts. Accordingly, all previously recognized compensation expense was reversed as of September 30, 2023, and the Company has ceased recognizing earnout compensation expense for all reporting periods occurring thereafter. Furthermore, during the quarter ended March 31, 2024, as well as subsequent thereto, events have occurred that have resulted in the Company notifying the sellers of Volumetric that they are no longer eligible to earn any of the milestone-based earnout payments outlined in the Volumetric acquisition agreement. Refer to the discussions in Note 11, Note 16, and Note 19 to the consolidated financial statements included in Part I, Item 1 of this Form 10-Q, for additional details regarding the events triggering, as well as the Company and third-party actions taken as a direct result of, the Company's issuance of notifications that the Volumetric earnout payments are no longer eligible to be earned.
Compensation and benefits expense decreased by $1.2 million for the three months ended March 31, 2024 primarily due to (1) lower severance expense incurred during the three months ended March 31, 2024 relative to severance expense recorded in connection with the execution of our 2023 Restructuring Plan during the three months ended March 31, 2023 and (2) lower ordinary salary, wages, and benefit costs due to headcount reductions that have occurred under our 2023 Restructuring Plan. Refer to the discussion of our 2023 Restructuring Plan within the "Recent Developments and Updates Regarding Strategic Initiatives" section of this MD&A for additional details regarding the Company's ongoing restructuring plan. Higher employee bonus expense accrued during the three months ended March 31, 2024 was substantially offset by lower stock compensation expense recognized during the period.
Amortization expense decreased by $1.1 million for the three months ended March 31, 2024 due to the impairment charges that reduced the carrying value of intangible assets included in the Oqton MOS and dp polar asset groups to $0 during the three months ended September 30, 2023 and December 31, 2023, respectively. Refer to the discussion of "Other Strategic Business Decisions and Cost Saving Initiatives" within the "Recent Developments and Updates Regarding Strategic Initiatives" section of this MD&A for additional details regarding the Company's plans and recent actions taken with respect Oqton and dp polar. Amortization expense attributable to intangible assets recorded in connection with the Company's July 1, 2023 acquisition of Wematter partially offset the lower amortization expense resulting from the impairment of the intangible asset balances previously included in the Oqton MOS and dp polar asset groups.
Third-party service provider and consulting cost increased $5.7 million for the three months ended March 31, 2024 primarily due to increased audit fees and third-party service provider costs attributable to the delayed filing of our 2023 Form 10-K. Third party service provider and consulting costs also increased due to (1) costs incurred in connection with our export control remedial compliance activities undertaken in lieu of payment of an additional settlement amount under the agreement reached with the DDTC in February 2023 (Refer to Note 16) and (2) costs attributable to certain finance transformation activities.
Accrued contingency expense increased due to the accrual of $1.5 million relating to a proposed settlement with the former shareholders and key employees of Volumetric during mediation. Refer to Note 16 and Note 19 to the consolidated financial statements included in Part I, Item 1 of this Form 10-Q for additional details regarding the ongoing mediation with the former shareholders and key employees of Volumetric.
Consolidated research and development expense
R&D expense for the three months ended March 31, 2024 increased $1.3 million, or 5.7%, to $23.5 million as compared to $22.2 million for the three months ended March 31, 2023. This increase in R&D expense was partially due to (1) a year-over-year ramp up of activities performed by our wholly-owned bio-tech subsidiary, Systemic Bio, which is focused on the design and manufacture of 3D-printed vascularized “organs-on-chips” for use in drug development by pharmaceutical industry customers and (2) R&D costs attributable to Wematter, which we acquired subsequent to the quarter ended March 31, 2023. Refer to the discussions of "Investing in Regenerative Medicine" and "Acquisition of Wematter" in the "Recent Developments and Updates Regarding Strategic Initiatives" section of this MD&A for additional details regarding Systemic Bio and the Wematter acquisition. In addition, the increase was partially due to unreimbursable R&D expense that continued to be incurred related to the kidney and liver regenerative medicine R&D program (1) after the focus of the Company's organ program with its strategic partner shifted solely to developing the capability to print lung scaffolds and (2) prior to any reallocation of resources committed to the program.
Consolidated loss from operations
Our operating loss for the three months ended March 31, 2024 was $39.9 million, compared to a $33.4 million operating loss for the three months ended March 31, 2023. The increase in our operating loss for the three months ended March 31, 2024 is due to lower products revenue, resulting in lower related gross profit, and higher R&D costs. The decrease in gross profit from product sales and increase in R&D costs were partially offset by an increase in services revenue and related gross profit and lower SG&A costs. Refer to the revenue and cost discussions above for additional details.
Non-operating income
The following table sets forth the components of non-operating income for the three months ended March 31, 2024 and 2023.
(in thousands)
| Non-operating income (expense): | Three Months Ended March 31, 2024 | March 31, 2023 |
|---|---|---|
| Foreign exchange gain (loss), net | $1,909 | $(372) |
| Interest income, net | 2,084 | 3,805 |
| Other income, net | 21,386 | 442 |
| Total non-operating income | $25,379 | $3,875 |
For the three months ended March 31, 2024, interest income, net decreased $1.7 million, as compared to the three months ended March 31, 2023, due to the Company's lower cash and cash equivalents balance during and as of three months ended March 31, 2024.
For the three months ended March 31, 2024, other income, net increased $20.9 million, as compared to the three months ended March 31, 2023, primarily due to the recognition of a $21.5 million gain on the extinguishment of debt during the three months ended March 31, 2024.
Net loss
The following table sets forth the net loss attributable to 3D Systems Corporation for the three months ended March 31, 2024, and 2023.
(in thousands, except per share amounts)
| Three Months Ended March 31, 2024 | March 31, 2023 | |
|---|---|---|
| Loss before income taxes | $(14,483) | $(29,521) |
| Provision for income taxes | (1,371) | (8) |
| Loss on equity method investment, net of income taxes | (247) | — |
| Net loss before redeemable non-controlling interest | (16,101) | (29,529) |
| Less: net loss attributable to redeemable non-controlling interest | (100) | (108) |
| Net loss attributable to 3D Systems Corporation | $(16,001) | $(29,421) |
| Net loss per common share: | ||
| Basic | $(0.12) | $(0.23) |
| Diluted | $(0.12) | $(0.23) |
Our tax provision for the three months ended March 31, 2024 was $1.4 million, as compared to a $0.0 million tax provision for the three months ended March 31, 2023. The increase in our tax provision for the three months ended March 31, 2024 was due to increased valuation allowances at foreign entities eliminating the benefit of our deferred tax assets at these entities. The tax provision for the three months ended March 31, 2023 was de minimis and significantly below both the U.S. and foreign jurisdictions' statutory rates due to the Company's reported losses, offset by valuation allowances against deferred tax assets generated by such losses.
The decrease in the net loss attributable to 3D Systems Corporation for the three months ended March 31, 2024, as compared to the net loss attributable to 3D Systems Corporation for the three months ended March 31, 2023, was primarily driven by the $21.5 million gain recognized in connection with our extinguishment of debt during the three months ended March 31, 2024, which more than offset the higher reported loss from operations, income tax provision, and loss on equity method investment for the period.
Non-GAAP Earnings
Adjusted EBITDA
Our Adjusted EBITDA decreased from negative $10.1 million for the three months ended March 31, 2023 to negative $20.1 million for the three months ended March 31, 2024. This decrease was partially driven by the $6.5 million increase in the Company's reported operating loss (as described above). In addition, as our reported operating loss includes certain non-cash and certain non-core operating expenses that are excluded from the determination of Adjusted EBITDA, our Adjusted EBITDA for the three months ended March 31, 2024 decreased due to the larger adjustments to our March 31, 2023 operating loss for (1) non-cash depreciation expense, amortization expense, and stock-based compensation expense and (2) non-core acquisition and divestiture expense and restructuring expense. Refer to the reconciliation of our reported Net Loss to Adjusted EBITDA (below) for additional details.
Reconciliation of Non-GAAP Measures
The table that follows provides a reconciliation of the Company's reported Net Loss to Adjusted EBITDA. Refer to the discussion of "How We Assess the Performance of Our Business" for additional information regarding Adjusted EBITDA, and why management believes this measure provides useful information regarding the Company's results of operations.
(in thousands)
| Three Months Ended March 31, 2024 | March 31, 2023 | |
|---|---|---|
| Net Loss | $(16,001) | $(29,421) |
| Interest (income) expense, net | (2,084) | (3,805) |
| Provision (benefit) for income taxes | 1,371 | 8 |
| Depreciation expense | 4,960 | 5,312 |
| Amortization expense | 2,313 | 3,239 |
| Stock-based compensation expense | 8,185 | 10,292 |
| Acquisition and divestiture-related expense | 53 | 2,677 |
| Legal and other related costs | 4,240 | 79 |
| Restructuring expense | 51 | 1,703 |
| Redeemable non controlling interest | (100) | (108) |
| Loss on equity method investments, net of tax | 247 | — |
| Gain on repurchase of debt | (21,518) | — |
| Other non-operating (income) expense, net | (1,777) | (70) |
| Adjusted EBITDA | $(20,060) | $(10,094) |
Segment Financial Results for the Three Months Ended March 31, 2024 and 2023
The Company has two reportable segments: Healthcare Solutions and Industrial Solutions. Our reportable segments are based upon the industry verticals that they serve and reflect how we report our financial results to the Company's chief operating decision maker ("CODM").
Our CODM evaluates the performance of our reportable segments based upon Segment Revenue and Segment Adjusted EBITDA. Segment Adjusted EBITDA excludes (1) expenses related to corporate functions such as human resources, finance, and legal — inclusive of salaries, benefits, and other related costs — and (2) the non-cash and non-core operating expenses and non-operating income and expenses that we exclude from our calculation of consolidated Adjusted EBITDA (as reflected in our reconciliation of our consolidated Net Loss to Adjusted EBITDA above). Unallocated corporate expenses are not discussed separately as any variances that had a significant impact on our operating results for the three months ended March 31, 2024, as compared to the three months ended March 31, 2023, are addressed in the discussion of our “Consolidated Financial Results for the Three Months Ended March 31, 2024 Compared to the Three Months Ended March 31, 2023” included above.
The following table presents revenue and Adjusted EBITDA for our Healthcare Solutions segment and our Industrial Solutions segment for the three months ended March 31, 2024 and 2023:
(in thousands)
| Segment Revenue March 31, 2024 | March 31, 2023 | Change | Segment Adjusted EBITDA March 31, 2024 | March 31, 2023 | Change | |
|---|---|---|---|---|---|---|
| Healthcare Solutions | $45,413 | $48,725 | $(3,312) | $3,720 | $5,065 | $(1,345) |
| Industrial Solutions | 57,492 | 72,511 | (15,019) | 2,082 | 6,902 | (4,820) |
| Total Segment Results | $102,905 | $121,236 | $(18,331) | $5,802 | $11,967 | $(6,165) |
Healthcare Solutions
Revenue
For the three months ended March 31, 2024, Healthcare Solutions revenue decreased $3.3 million, or 6.8%, as compared to the three months ended March 31, 2023. This decrease in segment revenue was driven by a $3.9 million decrease in products revenue, partially offset by a $0.6 million increase in services revenue.
For the three months ended March 31, 2024, the $3.9 million decrease in Healthcare Solutions products revenue was primarily due to a $4.0 million unfavorable impact of price/mix, as changes in sales volume resulted in a $0.1 million increase in products revenue. Although the net impact of changes in sales volume on Healthcare Solutions products revenue was insignificant, the $0.1 million increase consists of a significant increase in materials revenue due to changes in volume, substantially offset by a significant decrease in printer revenue due to changes in volume. During the three months ended March 31, 2024, sales of materials to our key customer in the dental industry increased as they returned to normalized levels; whereas, we experienced significantly lower material sales to this key customer during the three months ended March 31, 2023 due to the customer's higher inventory on hand during the prior year period. During the three months ended March 31, 2024, we experienced a significant decline in printer sales to our key customer in the dental industry, to which we also expect limited printer sales for the remainder of 2024, as this customer significantly expanded its printer capacity between 2022 and the quarter ended June 30, 2023. In addition, the current period volume-based increase in materials revenue for the Healthcare Solutions segment was partially offset by the loss of revenue attributable to our regenerative medicine kidney and liver R&D program, as well as a decrease in revenue attributable to our regenerative medicine lung R&D program for which there was lower activity during the quarter. Refer to the discussion of "Investing in Regenerative Medicine" with the "Recent Developments and Updates Regarding Strategic Initiatives" section of this MD&A.
For the three months ended March 31, 2024, the $4.0 million unfavorable impact of price/mix on products revenue reported by our Healthcare Solutions segment was primarily due to (1) the increased sales of materials to our key customer in the dental industry relative to prior year and as a percentage of the total materials sales and (2) lower pricing provided to this key dental industry customer relative to prior year.
The $0.6 million increase in Healthcare Solutions services revenue primarily relates to increased parts and maintenance revenue related to the installed printer base at our key dental industry customer.
Adjusted EBITDA
For the three months ended March 31, 2024, Adjusted EBITDA for our Healthcare Solutions segment decreased $1.3 million, or 26.6%, as compared to the three months ended March 31, 2023. For the three months ended March 31, 2024, the Healthcare Solutions segment realized an increase in gross profit due to the shift in sales volume and revenues from printers to higher margin materials sales; however, this increase in gross profit was more than offset by higher R&D costs primarily attributable to our investments in regenerative medicineR&D activities.
Industrial Solutions
Revenue
For the three months ended March 31, 2024, Industrial Solutions revenue decreased $15.0 million, or 20.7%, as compared to the three months ended March 31, 2023. This decrease in segment revenue was driven by a $16.4 million decrease in products revenue, partially offset by a $1.4 million increase in services revenue.
For the three months ended March 31, 2024, the $16.4 million decrease in Industrial Solutions products revenue was due to a $20.1 million decrease in revenue due to lower sales volumes for both printers and materials, offset by a $3.7 million favorable impact of changes in price/mix for both printers and materials sales. Lower printer sales volume and revenue for the three months ended March 31, 2024 is due to a concentration of significant printer sales arrangements occurring during the three months ended March 31, 2023; whereas, the Company did not benefit from similar arrangements during the current year period. Due to the significant sales price of certain of our 3D printers, this period-over-period change in the concentration of printer sales materially affected our reported revenue for the three months ended March 31, 2024. The favorable price/mix variance related to printers sales was due to lower pricing related to certain of the larger printer revenue arrangements that contributed to our higher printer sales volume during the three months ended March 31, 2023.
Materials sales volume and revenue also decreased for the three months ended March 31, 2024 due to certain larger materials sales arrangements that occurred during the three months ended March 31, 2023, but did not recur during the three months ended March 31, 2024. In certain cases, our customers held excess inventory during the three months ended March 31, 2024 as a result of their materials purchases occurring in 2023. The favorable price/mix variance related to materials sales was due to lower pricing related to certain of the larger materials revenue arrangements that contributed to our higher materials sales volume during the three months ended March 31, 2023.
The $1.4 million increase in Industrial Solutions services revenue primarily relates to increased parts manufacturing revenue, as well as revenue generated from a significant contract that had not been executed as of March 31, 2023.
Adjusted EBITDA
For the three months ended March 31, 2024, Adjusted EBITDA for our Industrial Solutions segment decreased $4.8 million, or 69.8%, as compared to the three months ended March 31, 2023. This decrease in Adjusted EBITDA is primarily attributable to the substantial decrease in segment gross profit attributable to the 20.7% decrease in segment revenue for the current period, partially offset by lower operating expense for the three months ended March 31, 2024.
Liquidity and Capital Resources
The following table sets forth the Company's operating working capital at March 31, 2024 and December 31, 2023.
(Dollars in thousands)
| March 31, 2024 | December 31, 2023 | Change $% | ||
|---|---|---|---|---|
| Cash and cash equivalents | $212,040 | $331,525 | $(119,485) | (36.0)% |
| Accounts receivable, net | 102,792 | 101,497 | 1,295 | 1.3% |
| Inventories | 145,628 | 152,188 | (6,560) | (4.3)% |
| 460,460 | 585,210 | (124,750) | (21.3)% | |
| Less: | ||||
| Current lease liabilities | 9,877 | 9,924 | (47) | (0.5)% |
| Accounts payable | 40,407 | 49,757 | (9,350) | (18.8)% |
| Accrued and other liabilities | 50,328 | 49,460 | 868 | 1.8% |
| 100,612 | 109,141 | (8,529) | (7.8)% | |
| Operating working capital | $359,848 | $476,069 | $(116,221) | (24.4)% |
We assess our liquidity in terms of our ability to generate cash to fund our operating, investing and financing activities. In doing so, we review and analyze our current cash on hand, the number of days our sales are outstanding, inventory turns, capital expenditure commitments and accounts payable turns. Our cash requirements, excluding acquisitions, primarily consist of funding working capital and capital expenditures. Differences between the amounts of working capital item changes in the cash flow statement and the balance sheet changes for the corresponding items are primarily the result of foreign currency translation adjustments and non-cash reserves.
At March 31, 2024, cash and cash equivalents totaled $212.0 million and had decreased $119.5 million since December 31, 2023. This decrease resulted primarily from cash used in operations of $25.5 million, capital expenditures of $3.2 million, and the use of $87.2 million for the repayment of borrowings.
Cash held outside the U.S. at March 31, 2024 was $62.5 million, or 29.5%, of total cash and cash equivalents, compared to $65.8 million, or 19.8%, of total cash and cash equivalents at December 31, 2023. As our previously unremitted earnings have been subjected to U.S. federal income tax, we expect any repatriation of these earnings to the U.S. (e.g., via dividends) would not incur significant federal and state taxes. However, these dividends would be subject to foreign withholding taxes that we estimate would result in the Company incurring tax costs in excess of the cost to obtain cash through other means. Cash equivalents are comprised of funds held in money market instruments and are reported at their current carrying value, which approximates fair value due to the short-term nature of these instruments. We strive to minimize our credit risk by investing primarily in investment grade, liquid instruments, and we limit exposure to any one issuer depending upon credit quality. See “Cash Flow” discussion below.
Cash Flow
The Company currently funds its operations, including working capital and capital expenditures, and acquisitions through cash on hand, cash equivalents, and financing activities as necessary. We expect that cash, cash equivalents, and other sources of liquidity, such as issuing equity or debt securities, subject to market conditions, will be available and sufficient to meet all foreseeable cash requirements. The following is a summary of the changes in the Company’s cash flows followed by a brief discussion of these changes:
(in thousands)
| Three Months Ended March 31, 2024 | March 31, 2023 | Dollar Change | |
|---|---|---|---|
| Cash flow used in operating activities | $(25,545) | $(27,722) | $2,177 |
| Cash flow (used in) provided by investing activities | (3,187) | 167,829 | (171,016) |
| Cash flow used in financing activities | (89,187) | (2,294) | (86,893) |
Cash flow from operations
For the three months ended March 31, 2024, cash used in operating activities was $25.5 million as compared to $27.7 million of cash used in operating activities for the three months ended March 31, 2023. This $2.2 million reduction in cash used in operating activities is reflective of a $10.8 million favorable impact of changes in working capital accounts, partially offset by a $8.6 million increase in our net loss for the three months ended March 31, 2024, as compared to March 31, 2023, when adjusted for the $21.5 million gain on the extinguishment of debt recognized during the three months ended March 31, 2024 and the following additional non-cash items recognized in each reporting period: depreciation, amortization, and accretion expense; stock-based compensation expense; non-cash operating lease expense; inventory obsolescence, and other non-cash losses and provisions. The $10.8 million favorable working capital impact was primarily the result of increased inventory buildup during the three months ended March 31, 2023 in anticipation of forecasted sales.
Cash flow from investing activities
For the three months ended March 31, 2024, cash used in investing activities primarily relates to capital expenditures of $3.2 million.
For the three months ended March 31, 2023, cash provided by investing activities was $167.8 million, which included $176.9 million of proceeds from the sales and maturities of short-term investments, partially offset by capital expenditures of $9.0 million.
Cash flow from financing activities
For the three months ended March 31, 2024, cash used in financing activities was $89.2 million, which primarily relates to $87.2 million used to repay borrowings and $1.7 million of taxes paid related to the net-share settlement of equity awards.
For the three months ended March 31, 2023, cash used in financing activities was $2.3 million, which was primarily attributable to taxes paid related to the net-share settlement of equity awards of $2.1 million.
Material Cash Requirements
The Company's material cash requirements consist of the following contractual and other obligations:
Indebtedness
At March 31, 2024, we had $214,378 of outstanding 0% convertible notes which mature in November of 2026. Management may consider pursuing additional long-term financing when it is appropriate in light of cash requirements for operations or other strategic opportunities, which could result in higher financing costs.
Purchase Commitments
We have purchase commitments under legally enforceable agreements for goods and services with defined terms as to quantity, price and timing of delivery. The Company has certain purchase commitments under agreements with remaining terms in excess of a year, which primarily relate to printer assemblies, inventory, capital expenditures, and software licenses. As of March 31, 2024, such purchase commitments totaled $20.9 million, with approximately $10.5 million, expected to be due within the next twelve months.
Leases
The Company had operating and financing lease obligations (inclusive of interest) of $103.9 million at March 31, 2024, primarily related to real estate and equipment leases, of which approximately $12.5 million in payments are expected over the remainder of 2024.
National Additive Manufacturing Innovation ("NAMI") Joint Venture
In March 2022, Dussur and 3D Systems signed an agreement to form a joint venture intended to expand the use of additive manufacturing within the Kingdom of Saudi Arabia and surrounding geographies, including the Middle East and North Africa. The joint venture is to enable the development of Saudi Arabia's domestic additive manufacturing production capabilities, consistent with the Kingdom’s ‘Vision 2030,’ which is focused on diversification of the economy and long-term sustainability. In February 2023, the Company became a shareholder in the joint venture and now owns 49% of its common stock. 3D Systems was committed to an initial investment of approximately $6.5 million of cash into the joint venture, all of which has been funded as of March 31, 2024. In May 2024, the Company made another investment in NAMI, as further discussed in Note 19 to the condensed consolidated financial statements included in Item 1 of this Form 10-Q. Additional future investments in the joint venture are contingent upon the achievement of certain milestones by the joint venture. The future impact that participation in the joint venture will have on the Company’s financial position and cash flows is not expected to be material other than any potential cash outflow(s) that may be required to fund contingent investments.
Sources of Funding to Satisfy Material Cash Requirements
The Company believes that it has the financial resources needed to meet its cash requirements during the next twelve months. Cash requirements for periods beyond the next twelve months will depend on, among other things, the Company’s profitability and its ability to manage working capital requirements.
Other Contractual Commitments
Convertible Note
As of March 31, 2024, the Company was in compliance with all covenants of the outstanding 0% convertible notes due November 2026. Subsequent to March 31, 2024, the Company has become non-compliant with certain terms of the Indenture related to the outstanding 0% convertible notes due 2026. Refer to Note 19 for details regarding the Company's non-compliance with the Indenture subsequent to March 31, 2024.
Indemnification
In the normal course of business we periodically enter into agreements to indemnify customers or suppliers against claims of intellectual property infringement made by third parties arising from the use of our products. Historically, costs related to these indemnification provisions have not been significant. We are unable to estimate the maximum potential impact of these indemnification provisions on our future results of operations.
To the extent permitted under Delaware law, we indemnify our directors and officers for certain events or occurrences, when the director or officer is, or was, serving at our request in such capacity, subject to limited exceptions. The maximum potential amount of future payments we could be required to make under these indemnification obligations is unlimited; however, we have directors’ and officers’ insurance coverage that may enable us to recover future amounts paid, subject to a deductible and to the policy limits. There is no assurance that the policy limits will be sufficient to cover all damages, if any.
Critical Accounting Estimates
Our condensed consolidated financial statements are prepared in accordance with GAAP. The preparation of these condensed consolidated financial statements requires us to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, costs and expenses, and related disclosures. On an ongoing basis, we evaluate our estimates and assumptions. Our actual results may differ from these estimates under different assumptions or conditions.
As of the date of this report, there have been no changes to our critical accounting estimates described in the 2023 Form 10-K that have had a material impact on our condensed consolidated financial statements and related notes.
See Note 2 to the consolidated financial statements in our 2023 Form 10-K for a summary of our significant accounting policies.
Forward-Looking Statements
Certain statements made in this Form 10-Q that are not statements of historical or current facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In many cases, you can identify forward-looking statements by terms such as “believes,” “belief,” “expects,” “may,” “will,” “estimates,” “intends,” “anticipates,” or “plans” or the negative of these terms or other comparable terminology.
Forward-looking statements are based upon management’s beliefs, assumptions and current expectations concerning future events and trends, using information currently available, and are necessarily subject to uncertainties, many of which are outside our control. Although we believe that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at or by which any such performance or results will be achieved. A number of important factors could cause actual results to differ materially from those expressed in or implied by the forward-looking statements. These factors include without limitation:
- impact on our business as a result of macroeconomic events, including the Russia-Ukraine war and other geopolitical risks, recession, supply chain disruptions and foreign exchange volatility;
- our ability to deliver products that meet changing technology and customer needs;
- our ability to identify strategic acquisitions, to integrate such acquisitions into our business without disruption and to realize the anticipated benefits of such acquisitions;
- impact of future write-off or write-downs of goodwill and intangible assets;
- the concentration of revenue and credit risk exposure from our largest customer;
- our ability to acquire and enforce intellectual property rights and defend such rights against third party claims;
- our ability to protect our intellectual property rights and confidential information, including our digital content, from third-party infringers or unauthorized copying, use or disclosure;
- failure of our information technology infrastructure or inability to protect against cyber-attack;
- our ability to predict quarterly sales and manage product inventory due to uneven sales cycle;
- our ability to generate net cash flow from operations;
- our ability to service our debt and ability to raise funds necessary to settle conversions of the Notes in cash, repay the Notes at maturity, or repurchase the Notes in the case of a fundamental change;
- our ability to remediate material weaknesses in our internal controls over financial reporting and maintain effective internal controls;
- fluctuations in our gross profit margins, operating income or loss and/or net income or loss;
- our ability to efficiently conduct business outside the U.S.;
- our dependence on our supply chain for components and sub-assemblies used in our 3D printers and other products and for raw materials used in our print materials;
- our ability to manage the costs and effects of litigation, investigations or similar matters involving us or our subsidiaries;
- product quality problems that result in decreased sales and operating margin, product returns, product liability, warranty or other claims;
- our ability to retain our key employees and to attract and retain new qualified employees, while controlling our labor costs;
- our ability to successfully develop and commercialize regenerative medicine products ourselves, or in conjunction with development partners;
- disruption in our management information systems for inventory management, distribution, and other key functions;
- compliance with U.S. and other anti-corruption laws, data privacy laws, trade controls, economic sanctions, and similar laws and regulations;
- our ability to maintain our status as a responsible contractor under federal rules and regulations;
- changes in, or interpretation of, tax rules and regulations; and
- the other factors discussed in the reports we file with or furnish to the SEC from time to time, including the risks and important factors set forth in additional detail in Item 1A. “Risk Factors” in the 2023 Form 10-K.
Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements included herein are made only as of the date of this Form 10-Q and we undertake no obligation to publicly update or revise any forward-looking statement made by us or on our behalf, whether as a result of new information, future developments, subsequent events or circumstances or otherwise, except as required by law. All subsequent written or oral forward-looking statements attributable to us or individuals acting on our behalf are expressly qualified in their entirety by the cautionary statements referenced above.
Market risk
As filed, 339 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
For a discussion of market risks at December 31, 2023, refer to Item 7A. “Quantitative and Qualitative Disclosures about Market Risk” in our 2023 Form 10-K. During the three months ended March 31, 2024, there were no material changes or developments that would materially alter the market risk assessment performed as of December 31, 2023.
Controls and procedures
As filed, 1,448 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
As of March 31, 2024, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) pursuant to Rules 13a-15 and 15d-15 under the Exchange Act. Based on this evaluation, management has concluded that our disclosure controls and procedures were not effective as of March 31, 2024 due to the material weaknesses discussed in our 2023 Form 10-K.
Changes in Internal Control Over Financial Reporting
We are in the process of implementing certain changes to our internal controls to remediate the material weaknesses, as disclosed in Part II, Item 9A, "Controls and Procedures", of our 2023 Form 10-K. Due to the close proximity of the respective dates in which we concluded our evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of December 31, 2023 and March 31, 2024, there were no changes in the Company’s internal control over financial reporting during the three months ended March 31, 2024 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
Risk factors
As filed, 154 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
There are no material changes to the risk factors previously disclosed in our 2023 Form 10-K in response to Item 1A. “Risk Factors” in the 2023 Form 10-K.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-01-01 to 2024-03-31 | $102.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2024-01-01 to 2024-03-31 | $62.0m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2024-01-01 to 2024-03-31 | $40.9m | us-gaap:GrossProfit |
| Research and development | 3 months2024-01-01 to 2024-03-31 | $23.5m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2024-01-01 to 2024-03-31 | $57.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2024-01-01 to 2024-03-31 | −$39.9m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2024-01-01 to 2024-03-31 | $1.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-01-01 to 2024-03-31 | −$16.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-01-01 to 2024-03-31 | −$0.12 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-01-01 to 2024-03-31 | −$0.12 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-01-01 to 2024-03-31 | 130,820,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2024-01-01 to 2024-03-31 | −$25.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2024-01-01 to 2024-03-31 | $3.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-03-31 | $212.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-03-31 | $505.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-03-31 | $857.2m | us-gaap:Assets |
| Current liabilities | At period end2024-03-31 | $145.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-03-31 | $446.9m | us-gaap:Liabilities |
| Long-term debt | At period end2024-03-31 | $211.1m | us-gaap:LongTermDebtNoncurrent |
Source: SEC EDGAR, the filing index for accession 0000910638-24-000035. Last ingested by Listed: Nov 15, 2026, 00:01 ET. Listed shows no prices and gives no investment advice.